Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on recent business development activity, including three recently closed transactions that are expected to enhance the company’s antibody-drug conjugate (ADC) capabilities. Immunome acquired worldwide, exclusive rights to:
- A panel of antibodies against an undisclosed solid tumor target from Nectin Therapeutics
- A panel of antibodies against an undisclosed solid tumor target from Bluefin Biomedicine
- Four antibodies against undisclosed targets from OncoResponse
In addition, the company previously announced the purchase of 28 antibodies from Atreca in May 2024 and the exclusive license of IM-1021 along with the underlying ADC platform technology from Zentalis in January 2024. None of the acquired antibodies are known to share the same target as an FDA approved ADC.
“Immunome’s long-term vision remains centered on a broad pipeline of targeted therapies, particularly ADCs against novel targets,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “Focused business development activity complements our highly productive internal discovery efforts and has led to an advancing pipeline of product candidates.”
“Successful ADC development requires addressing the unique biology of each target with appropriate antibodies, linkers and payloads,” added Jack Higgins, PhD, Chief Scientific Officer of Immunome. “Our research team has identified multiple promising ADC targets. We have also established a toolbox that includes multiple linkers, our differentiated proprietary TOP1 inhibitor and numerous antibodies. We believe that the next generation of ADCs will bring tremendous benefit to cancer patients.”
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “believe,” “expected,” and similar expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, Immunome’s expectations around recently closed transactions; the next generation of ADCs’ ability to bring benefit to cancer patients; Immunome’s expected timeline for regulatory filings; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; Immunome’s ability to grow and successfully execute on its business plan, including the development and commercialization of its pipeline and integration of newly acquired assets; the risk that prior experience and success of Immunome’s management team is not indicative of future success; and other risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 14, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725411821/en/
Contacts
Max Rosett
Chief Financial Officer
investors@immunome.com
